Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 102-Week, Open Label, Multicenter Trial To Investigate The Efficacy Of Macugen For The Preservation Of Visual Function In Subjects With Neovascular Age-Related Macular Degeneration (AMD) And To Assess The Benefit Of Treating Early Choroidal Neovascularization (CNV).

NCT00327470 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00327470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00327470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 102-Week, Open Label, Multicenter Trial To Investigate The Efficacy Of Macugen For The Preservation Of Visual Function In Subjects With Neovascular Age-Related Macular Degeneration (AMD) And To Assess The Benefit Of Treating Early Choroidal Neovascularization (CNV).
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Terminated
Start date
July 31, 2006
Completion date
August 31, 2009
Enrollment
288 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration (amd), choroidal neovascularization (cnv), macular degeneration